# A Single-center, Open, Randomized, Single-dose, Cross-over Bioequivalence Study to Evaluate the Effects of the Test Formulation Abalparatide Injection and the Reference Formulation Abalparatide Injection (Tymlos®) in Healthy Adult Subjects

> **NCT06753864** · PHASE1 · NOT_YET_RECRUITING · sponsor: **The Affiliated Hospital of Qingdao University** · enrollment: 32 (estimated)

## Conditions studied

- Osteoporosis

## Interventions

- **DRUG:** Test (T)
- **DRUG:** Reference (R)

## Key facts

- **NCT ID:** NCT06753864
- **Lead sponsor:** The Affiliated Hospital of Qingdao University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-01-02
- **Primary completion:** 2025-01-09
- **Final completion:** 2025-05-01
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2024-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06753864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06753864, "A Single-center, Open, Randomized, Single-dose, Cross-over Bioequivalence Study to Evaluate the Effects of the Test Formulation Abalparatide Injection and the Reference Formulation Abalparatide Injection (Tymlos®) in Healthy Adult Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06753864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*